Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia

Stefano Molica, Gaetano Vitelli, Domenico Levato, Diana Giannarelli, Angelo Vacca, Antonio Cuneo, Franceso Cavazzini, Roberto Squillace, Rosanna Mirabelli, Giovanna Digiesi

Research output: Contribution to journalArticle


Background and Methods: Serum levels of matrix metalloproteinase-9 (MMP-9) which agree with progression in solid and haematological tumours were correlated to the risk of disease progression in 62 patients with early (Binet stage A) B-cell chronic lymphocytic leukaemia (CLL). Sera were taken at diagnosis and tested by an enzyme-linked immunosorbent assay. Results: MMP-9 levels positively correlated with haemoglobin levels (P = 0.03) and platelet count (P = 0.03). No association was found with main clinico-haematological features representative of tumour mass, such as peripheral blood lymphocytosis, bone marrow histology, Rai substages and β-2 microglobulin (β-2m). A cut-off of MMP-9 levels corresponding to 33rd percentile (203 ng/mL) or higher identified earlier upstaging and shorter progression-free survival. MMP-9 was a significant prognostic marker in multivariate analysis and partially independent of Rai substages, which suggests its inclusion into such a staging system to better stratify prognostically Rai stages I and II patients. Conclusions: MMP-9 serum levels predict disease behaviour and help to refine the prognosis of stage A CLL patients.

Original languageEnglish
Pages (from-to)373-378
Number of pages6
JournalEuropean Journal of Haematology
Issue number6
Publication statusPublished - Jun 1 2003



  • Disease progression
  • Matrix metalloproteinase-9
  • Stage A chronic lymphocytic leukaemia

ASJC Scopus subject areas

  • Hematology

Cite this